Document:

Consent of Deloitte & Touche LLP

 Exhibit 10.1 
  
 INDEPENDENT AUDITORS’ CONSENT 
  
 We consent to the incorporation by reference in Registration Statements No. 33-52722 and No. 33-92818 of Tomkins plc on Form
S-8 of our report dated February 26, 2004, except for Note 26, as to which the date is May 18, 2004 (which report expresses an unqualified opinion and includes explanatory paragraphs relating to the differences between accounting principles
generally accepted in the United States of America and the effect that the application of the latter would have on the determination of net income and shareholders’ equity), appearing in this Annual Report on Form 20-F of Tomkins plc and its
subsidiaries for the year ended January 3, 2004. 
  

	
	
	/s/     DELOITTE & TOUCHE LLP        
	

	 Deloitte & Touche LLP
 London, England

  
 May 18, 2004Certification of CEO  and Chief Financial Officer

 Exhibit 10.2 
  
 CERTIFICATION 
  
 I, James Nicol, certify that: 
  

	 	1)	I have reviewed this Annual Report on Form 20-F of Tomkins plc. 

  

	 	2)	Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light
of the circumstances under which such statements were made, not misleading with respect to the period covered by this Annual Report; 

  

	 	3)	Based on my knowledge, the financial statements, and other financial information included in this Annual Report, fairly present in all material respects the financial condition,
results of operations and cash flows of the company as of, and for, the periods presented in this Annual Report; 

  

	 	4)	The company’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a –
15(e) and 15d – 15(e) for the company and have: 

  

	 	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Annual Report is being prepared; 

  

	 	b)	evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this Annual Report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this Annual Report based on such evaluation; and 

  

	 	c)	disclosed in this Annual Report any change in the company’s internal control over financial reporting that occurred during the period covered by this Annual Report that has
materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and 

  

	 	5)	The company’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors
and the audit committee of the company’s board of directors (or persons performing the equivalent functions): 

  

	 	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
company’s ability to record, process, summarize and report financial information; and 

  

	 	b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

  

	
	
	/s/    JAMES NICOL        
	

	 By: James Nicol
 Chief Executive Officer

  
 May 18, 2004 
  

 Exhibit 10.2 continued 
  
 CERTIFICATION 
  
 I, Kenneth Lever, certify that: 
  

	 	1)	I have reviewed this Annual Report on Form 20-F of Tomkins plc. 

  

	 	2)	Based on my knowledge, this Annual Report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light
of the circumstances under which such statements were made, not misleading with respect to the period covered by this Annual Report; 

  

	 	3)	Based on my knowledge, the financial statements, and other financial information included in this Annual Report, fairly present in all material respects the financial condition,
results of operations and cash flows of the company as of, and for, the periods presented in this Annual Report; 

  

	 	4)	The company’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a –
15(e) and 15d – 15(e) for the company and have: 

  

	 	a)	designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this Annual Report is being prepared; 

  

	 	b)	evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this Annual Report our conclusions about the effectiveness of the disclosure
controls and procedures, as of the end of the period covered by this Annual Report based on such evaluation; and 

  

	 	c)	disclosed in this Annual Report any change in the company’s internal control over financial reporting that occurred during the period covered by this Annual Report that has
materially affected, or is reasonably likely to materially affect, the company’s internal control over financial reporting; and 

  

	 	5)	The company’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company’s auditors
and the Audit Committee of the company’s board of directors (or persons performing the equivalent functions): 

  

	 	a)	all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
company’s ability to record, process, summarize and report financial information; and 

  

	 	b)	any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s internal control over financial reporting.

  

	
	
	/s/    KENNETH LEVER        
	

	 By: Kenneth Lever
 Chief Financial Officer

  
 May 18, 2004Certification of CEO and Chief Financial Officer (Sarbanes Oxley Act)

 Exhibit 10.3 
  
 CERTIFICATION OF CEO AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002 
  
 In connection with
the Annual Report on Form 20-F of Tomkins plc (the “Company”) for the fiscal year ended January 3, 2004 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), James Nicol, as Chief Executive
Officer of the Company, and Kenneth Lever, as Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his
knowledge; 
  

	 	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and 

  

	 	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. 

  

	
	
	/s/    JAMES NICOL        
	

	 By: James Nicol
 Chief Executive Officer

	
	/s/    KENNETH LEVER        
	

	 By: Kenneth Lever
 Chief Financial Officer

  
 May 18, 2004 
  
 This certification accompanies the Report pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 and shall not, except as to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for purposes of Section 18 of the Securities and Exchange Act of 1934. 
  
 A signed original of this written statement required by Section 906 of the
Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.Marketing Services Agreement

 [CONFIDENTIAL TREATMENT REQUESTED. CONFIDENTIAL PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND FILED SEPARATELY
WITH THE COMMISSION.] 
  
 Exhibit 10.26 
  
 MARKETING SERVICES AGREEMENT 
  
 This Marketing Services Agreement (the “Agreement”) is entered into
as of Apr 2, 2003 (the “Effective Date”) by and between Charles River Laboratories, Inc., a Delaware corporation with its principal place of business at 251 Ballardvale Street, Wilmington, Massachusetts 01887 (“Charles River”),
Xenogen Corporation, a Delaware corporation with its principal place of business a 860 Atlantic Avenue, Alameda, California, 94501 (“Xenogen”) and Xenogen Biosciences Corporation, an Ohio corporation with its principal place of business at
5 Cedar Brook Drive, Cranbury, NJ 08512 (“XenogenBio”). 
  
 Whereas, Charles River is a supplier of laboratory research models and related products and services for use in biomedical research and development; and 
  
 Whereas, XenogenBio is a wholly owned subsidiary of Xenogen, and a creator of laboratory research models and related
services for use in biomedical research and development (“Creation Services”), which Creation Services are more fully described on Exhibit A attached hereto; and 
  
 Whereas, Charles River, Xenogen and XenogenBio wish to enter into a business arrangement that will enable them to work
together to market and sell the Creation Services. 
  
 Now,
therefore, in consideration of the mutual covenants herein contained and for other good and valuable consideration, the parties hereto, intending to be legally bound, agree as follows: 
  

	1.	Joint Responsibilities. Charles River and Xenogen will coordinate efforts and assist each other in the marketing and selling of the Creation Services.

  

	2.	Responsibilities of Charles River. Charles River shall: 

  

	 	(a)	Market the Creation Services in the United States and Canada (“North America”) and forward information regarding sales leads of the Creation Services to XenogenBio in
accordance with the Marketing Plan attached hereto as Exhibit B (“Marketing Plan”). 

  

	 	(b)	Participate in quarterly conference calls with XenogenBio to provide updates and manage the marketing collaboration. 

  

	 	(c)	Provide quarterly reports to XenogenBio specifying the marketing activities undertaken, together with a summary of all sales leads previously provided to XenogenBio.

  

	 	(d)	Designate a representative to be the primary contact for the management and execution of this Agreement. 

  

	3.	Responsibilities of Xenogen and XenogenBio. 

  

	 	(a)	Xenogen and XenogenBio shall pursue all sales leads provided by Charles River, including without limitation, closing sales and servicing customers in the manner that Xenogen and
each would ordinarily and typically pursue and close similar sales leads. 

  

 Confidential - Xenogen Corporation 

	 	(b)	XenogenBio shall perform Creation Services for customers, in a timely fashion and in accordance with customer specifications with the same level of diligence and skill as XenogenBio
ordinarily and typically provides for its other customers. 

  

	 	(c)	Xenogen and XenogenBio, as appropriate, shall provide training for Charles River’s sales force and other personnel as set forth in the Marketing Plan. 

 

	 	(d)	Xenogen and XenogenBio, as appropriate, shall provide technical content for the marketing and sales materials described in the Marketing Plan and assist Charles River in the
creation of the technical content for the marketing and sales materials. 

  

	 	(e)	Xenogen and XenogenBio, as appropriate, shall participate in quarterly conference calls with Charles River to provide updates and manage the marketing collaboration.

  

	 	(f)	XenogenBio shall provide quarterly written reports to Charles River specifying the sales leads received, both directly and indirectly. 

  

	 	(g)	Xenogen shall designate a representative to be the primary contact for the management and execution of this Agreement. 

  

	4.	Compensation. Either of Xenogen or XenogenBio shall make the following payments to Charles River; 

  

	 	(a)	Xenogen or XenogenBio shall pay Charles River an annual nonrefundable fee ***. 

  

	 	(b)	Subject to Section 4(d) and 4(e) below, Xenogen or XenogenBio shall pay Charles River a commission on revenue from the Creation Services (“Revenue”) ***.

  

	 	(c)	Revenue shall mean the amount invoiced by XenogenBio to third parties for the Creation Services less: 

  

	 	(i)	charges for insurance, freight and other transportation costs directly related to the delivery of the Creation Services to the extent included in the gross invoiced sales price;

  

	 	(ii)	credits or allowances actually granted upon claims, rejections or returns of sales of the Creation Services; and 

  
 Confidential - Xenogen Corporation 
  

	***	Confidential treatment requested 

	 	(iii)	any sales, excise, use or ad valorem taxes and any direct governmental charges included in such invoice as a separately stated charge, as adjusted for rebates, charge backs and
refunds. 

  

	 	(d)	The parties agree and acknowledge that with respect to those certain customers set forth on Exhibit D attached hereto, only the amounts received from those customers in excess of
the amounts set forth on Exhibit D shall be included in Revenue for the purposes of this Agreement. 

  

	 	(e)	All commission payments shall be made on a calendar quarter basis within thirty (30) days after the end of each quarter for which commissions are due. Each commission payment shall
be accompanied by a written report setting forth the calculation of Revenue and the calculation of commission due. Such reports shall include at least the total amount invoiced for the Creation Services, the amount of the allowable deductions and
the amount of the total commissions due. If no commission payments are due for a particular quarter, the report shall be delivered as required above and shall state that no commissions are due. 

  

	 	(f)	All commissions shall be payable in full in United States Dollars, regardless of the countries in which sales are made. For the purpose of computing Revenue for which a currency
other than United States Dollars is received, such currency shall be converted into United States dollars at the exchange rate for buying United States Dollars set forth in The Wall Street Journal for the last business day of the calendar
quarter. 

  

	 	(g)	Any payment due and payable by Xenogen and XenogenBio to Charles River under this Agreement not made on the date such payment is due and payable, including without limitation any
installment of the Annual Fee, shall bear interest as of the date such payment was due and shall continue to accrue interest until such payment is made at a rate equal to the lesser of one and one-half percent (1.5%) interest per month or the
maximum rate permitted by applicable law. 

  

	5.	 Record Retention; Audits. XenogenBio shall keep for three (3) years from the date of each commission payment complete and accurate records of sales by
XenogenBio of the Creation Services in sufficient detail to allow the accruing commissions hereunder to be determined accurately. Charles River shall have the right for a period of three (3) years after receiving any report or statement with respect
to commissions due and payable to appoint an independent certified public accountant, at Charles’s expense, to inspect the relevant records of Xenogen to verify such report or statement. XenogenBio shall make its records available for
inspection by such independent certified public accountant during regular business hours at such place or places where such records are customarily kept, upon reasonable notice from Charles River, solely to verify the accuracy of the reports and
payments. Such inspection right shall not be exercised more than once in any calendar year. Charles River agrees to hold in strict confidence all information concerning commission payments and reports, and all information learned in the course of
any audit or inspection, except to the extent necessary for Charles River to reveal such information in order to enforce its rights under this Agreement or if disclosure is required by law, regulation or judicial order. The results of each
inspection, if any, shall be binding on both Parties. The cost of the inspection shall be borne by Charles River, provided however that if the inspection reveals that the records were not kept as required hereunder, or that an underpayment of ten

  

 Confidential - Xenogen Corporation 

	 	 
percent (10%) or more has occurred in any quarterly period, XenogenBio shall pay the cost of the inspection, together with the underpayment and interest
calculated as set forth above. 

  

	6.	Term and Termination. 

  

	 	(a)	The term of the Agreement shall expire twenty-four (24) months following the Effective Date. The parties acknowledge that in order for the Creation Services to be included in the
next annual Charles River printed catalogue of services (the “Charles River Catalogue”), this Agreement must be in full force and effect on October 1 of the preceding year and not due to expire during the next full calendar year. This
Agreement may be renewed by the mutual agreement of the parties. 

  

	 	(b)	The Agreement may be terminated at any time by any party in the following ways: 

  
 (i) by Xenogen, XenogenBio or Charles River, upon written notice effective immediately, in the event any of them acquires or
is acquired by a competitor; or 
  
 (ii) upon written notice in
the event (a) that any party shall have dissolved, ceased active business operations or liquidated itself, or (b) of bankruptcy or insolvency proceedings, including any proceeding under Title 11 of the United States Code, have been brought by or
against another party and remains undismissed or unwithdrawn for a period of thirty (30) days, or (c) an assignment has been made for the benefit of another party’s creditors or a receiver of such party’s assets has been appointed

  
 (iii) by a non-defaulting party upon thirty (30) days’
written notice to the defaulting party (which notice shall specify the nature of the default), if any party shall have failed in the full and timely observance or performance of any of its covenants or obligations under this Agreement, provided
however that if the default is cured within the thirty (30) day period, the notice shall be withdrawn and of no effect. Notwithstanding anything contained herein to the contrary, upon the third occurrence of the same or similar default in a twelve
(12) month period, no thirty (30) day cure period shall be available and the non-defaulting party may terminate the Agreement immediately upon written notice. 
  

	 	(c)	In the event of termination by either party, Xenogen and XenogenBio shall remain responsible for all payments due and payable through the termination date, except as otherwise set
forth herein.*** 

  
 Confidential - Xenogen
Corporation 
  

	***	Confidential treatment requested 

	 	 
Charles River shall own all marketing materials developed pursuant to this Agreement after the termination or expiration of this Agreement for any reason,
although Charles River shall no longer have a license to use any of Xenogen’s trademarks or service marks in any manner. 

  

	 	(d)	Termination and expiration of this Agreement for any reason shall be without prejudice to the rights and obligations of the parties provided in Sections 4, 5, 6, 7, 8, 9, 10, 11,
12, 13, 14 and 21, all of which shall survive such termination and any other rights or remedies provided at law or equity which either party may otherwise have against the other. 

  

	7.	Confidentiality. 

  

	 	(a)	The parties anticipate that they will exchange proprietary and confidential information during the term of this Agreement. The parties shall identify, in writing, such information
as confidential and/or proprietary. Each party shall maintain such information in confidence and will employ reasonable and appropriate procedures to prevent its unauthorized publication or disclosure unless required to disclose such information.
Neither party shall use the other party’s proprietary or confidential information for any purpose other than in performance of this Agreement. Each party, upon the others request, will return all the confidential information disclosed or
transferred to it by the other party pursuant to this Agreement, including all copies and extracts of documents and all manifestations in whatever form, within sixty (60) days of the request following the termination of this Agreement; provided that
one copy of the confidential information may be retained in inactive archives solely for the purpose of ensuring compliance herewith. The obligations of confidentiality set forth in this paragraph will survive termination or expiration of this
Agreement for a period of five (5) years. The confidentiality provisions of this paragraph shall not apply to any part of such information, for which it can be established by competent written proof that: 

  

	 	(i)	is known to the receiving party, other than under an obligation of confidentiality, at the time it was obtained from the disclosing party; 

  

	 	(ii)	is acquired by receiving party from a third party and such third party did not obtain such information directly or indirectly from the disclosing party under obligation not to
disclose; 

  

	 	(iii)	is or becomes published or otherwise in the public domain other than by violation of this Agreement by the receiving party; or 

  

	 	(iv)	is independently developed by the receiving party without reference to or use of the information provided by the disclosing party. 

  

	 	(b)	Neither Xenogen nor XenogenBio, on the one hand, or Charles River may publicly disclose the existence or terms of this Agreement without the prior written consent of the other
provided, however, that Charles River may disclose the existence of the Agreement for the purposes of marketing and selling the Creation Services and any party may make such a disclosure to the extent required by law, including the rules of a stock
exchange on which it is listed. Such disclosure shall be on reasonable notice to the other parties and after taking all reasonable steps to maintain confidentiality.*** 

  
 Confidential - Xenogen Corporation 
  

	***	Confidential treatment requested 

	8.	Trademarks and Copyrights. Xenogen grants Charles River a non-exclusive license in its trademarks, service marks, tradenames and copyrights related to the Creation Services
(the “Xenogen Rights”) for the term of this Agreement solely for the purposes of marketing and selling the Creation Services as described in the Marketing Plan. Xenogen reserves all rights not expressly granted herein. Charles River
acknowledges that it has no interest in the Xenogen Rights other than the licenses granted under this Agreement, and that Xenogen will remain the sole and exclusive owner of all right, title and interest in the Xenogen Rights. Charles River agrees
that Charles River’s use of the Xenogen Rights and any good will in such trademarks, service marks, tradenames and copyrights resulting from Charles River’s use will inure solely to the benefit of Xenogen and will not create any right,
title or interest for Charles River in the Xenogen Rights. Charles River shall not contest, oppose or challenge Xenogen’s ownership of the Xenogen Rights. Charles River agrees that it will do nothing to impair Xenogen’s ownership or rights
in the Xenogen Rights. Charles River shall not, during the term of this Agreement or thereafter, register, use, or attempt to obtain any right in and to any Xenogen Right (other than those rights granted herein) or in and to any name, logo or
trademark confusingly similar thereto or any derivative work of a Xenogen Right. Charles River agrees that at no time during or after the term of this Agreement to challenge or assist others to challenge the Xenogen Rights or the registration
thereof or attempt to register any trademarks, marks or trade names confusingly similar to such Xenogen Rights or that are derivative works of a Xenogen Right. Charles River shall not use any Xenogen Right or other proprietary mark of Xenogen or
Xenogen’s suppliers or licensors in a manner that has not been approved by Xenogen, and shall only use such Xenogen Rights in conformity with the style and usage developed by Xenogen. 

  

	9.	Warranties and Representations. 

  

	 	(a)	XenogenBio warrants that it owns or has rights of sufficient scope to the intellectual property included within the Creation Services, and that, as of the Effective Date, it is not
the subject of a claim or suit by a third party that XenogenBio’s own marketing and sale of the Creation Services infringes the intellectual property rights of such third party. 

  

 Confidential - Xenogen Corporation 

	 	(b)	Charles River, Xenogen and XenogenBio each represents and warrants to the other, as of the Effective Date, as follows: 

  
 (i) It is a corporation duly organized, validly existing and is in good
standing under the laws of the state in which it is incorporated, is qualified to do business and is in good standing as a foreign corporation in each jurisdiction in which the performance of its obligations hereunder requires such qualification and
has all requisite power and authority, corporate or otherwise, to conduct its business as now being conducted, to own, lease and operate its properties and to execute, deliver and perform this Agreement. 
  
 (ii) The execution, delivery and performance by it of this Agreement have
been duly authorized by all necessary corporate action and do not and will not (a) require any consent or approval of its stockholders or (b) violate any provision of any agreement, law, rule, regulation, order, writ, judgment, injunction, decree,
determination or award presently in effect having applicability to it or any provision of its charter documents. 
  
 (iii) This Agreement is a legal, valid and binding obligation of it enforceable against it in accordance with its terms and conditions. 
  
 (iv) It is not under any obligation to any person, or entity, contractual or
otherwise, that is conflicting or inconsistent in any respect with the terms of this Agreement or that would impede the diligent and complete fulfillment of its obligations hereunder and that it has all power and authority under all instruments or
agreements to which it is a party to enter into this Agreement and to perform its obligations hereunder. 
  

	10.	Warranty Disclaimer. EXCEPT AS STATED ABOVE, EACH PARTY DISCLAIMS ALL WARRANTIES, WHETHER EXPRESS, IMPLIED OR STATUTORY, WRITTEN OR ORAL, INCLUDING WITHOUT LIMITATION, ANY
WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR FOR NON-INFRINGEMENT OF A PATENT, TRADEMARK OR OTHER INTELLECTUAL PROPERTY RIGHT. 

  

	11.	Indemnification and Covenant not to Sue. 

  

	 	(a)	 In the event of any claim or allegation against Charles River by a third party of (i) infringement or misappropriation of copyright, patent, trade secret or any
other intellectual property right included within the Creation Services arising out of XenogenBio’s performance of such Creation Services, or (ii) breach of warranty by XenogenBio relating to the Creation Services performed for such third
party, personal injury or product liability or any other matter regarding Charles River’s marketing or advertising of the Creation Services and related to XenogenBio’s performance of such Creation Services for such third party, or (iii)
any other matter arising from the negligence or wilful misconduct of Xenogen or XenogenBio hereunder, Xenogen and XenogenBio will, at their expense, indemnify, defend and hold Charles River harmless from any such claim, 

  

 Confidential - Xenogen Corporation 

	 	 
damages, losses, liabilities, fines, penalties, costs and expenses (including reasonable attorneys’ fees) (any of the foregoing, a “Claim”)
incurred by Charles River and pay any damages awarded or settlement reached in connection therewith, provided that Charles River shall promptly notify Xenogen of any such Claim, and Xenogen shall have the sole and exclusive authority to defend
and/or settle any such Claim; provided that Charles River shall have the right to participate, at its own expense, with counsel of its own choosing in the defense and/or settlement of such Claim. The foregoing indemnification shall not apply to
amounts paid with respect to settlement of any Claim if such settlement is effected without the consent of Charles River, which consent will not be unreasonably withheld or delayed. Xenogen and XenogenBio shall keep Charles River informed of the
progress of such litigation. 

  

	 	(b)	Xenogen and XenogenBio acknowledge and agree that any services performed by Charles River on genetically manipulated stocks and strains delivered to Charles River by non-affiliated
third parties, other than creation services utilizing (i) those patented technologies that XenogenBio uses in the course of performing any of the Creation Services and has the exclusive right to sublicense to others, or (ii) services or materials
related to detection, observation and reporting of light emitted from within living mammals (the “CRL Services”) do not infringe upon Xenogen’s or XenogenBio’s intellectual property rights. Xenogen and XenogenBio agree that
neither will bring or threaten suit against Charles River for infringement of any of Xenogen’s or XenogenBio’s intellectual property rights, cooperate with third parties in bringing suit against Charles River for infringement of any of
Xenogen’s or Xenogen’s intellectual property rights or otherwise seek to impose legal or equitable constraints on Charles River for infringement of Xenogen’s or XenogenBio’s intellectual property rights due to the CRL Services.

  

	 	(c)	In the event of any claim or allegation against Xenogen or XenogenBio by a third party arising from (i) the negligence or wilful misconduct of Charles River hereunder, or (ii)
Charles River’s marketing and sales of the Creation Services, Charles River will, at its expense, indemnify, defend and hold Xenogen and XenogenBio harmless from any such Claim, incurred by Xenogen and XenogenBio and pay any damages awarded or
settlement reached in connection therewith, provided that Xenogen or XenogenBio shall promptly notify Charles River of any such Claim, and Charles River shall have the sole and exclusive authority to defend and/or settle any such Claim; provided
that Xenogen and XenogenBio shall have the right to participate, at their own expense, with counsel of their own choosing in the defense and/or settlement of such Claim. The foregoing indemnification shall not apply to amounts paid with respect to
settlement of any Claim, if such settlement is effected without the consent of Xenogen or XenogenBio, which consent will not be unreasonably withheld or delayed. Charles River shall keep Xenogen and XenogenBio informed of the progress of such
litigation. 

  

	12.	 Limitation of Liability. IN NO EVENT SHALL ANY PARTY BE LIABLE TO THE OTHER FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES INCURRED BY THE

  

 Confidential - Xenogen Corporation 

	 	 
OTHER, INCLUDING, BUT NOT LIMITED TO, LOSS OF PROFITS, LOSS OF OPPORTUNITIES, LOSS OF DATA, LOSS OF USE DAMAGES OR COST OF PROCUREMENT OF SUBSTITUTE GOODS OR
SERVICES, ARISING OUT OF THIS AGREEMENT. 

  
 ***

  

	14.	Notices. All notices shall be in writing mailed via certified mail, return receipt requested, courier, or facsimile transmission addressed as follows, or to such other
address as may be designated from time to time: 

  

			
	If to Xenogen	  	 Xenogen Corporation
 860 Atlantic
Avenue
 Alameda, CA 94501
 Attn: V.P., Corporate
Development

		
	With a copy to:	  	 Xenogen Biosciences
 5 Cedar Brook Drive
 Cranbury, NJ 08512
 Attn: Legal Department

		
	If to Charles River:	  	 Charles River Laboratories, Inc.
 251 Ballardvale
Street
 Wilmington, MA 01887
 Attn: General
Counsel

  
 Notices shall be
deemed given as of the date received. 
  

	15.	Relationship of Parties. The parties to this Agreement are independent contractors. There is no relationship of partnership, joint venture, employment, franchise or agency
between the parties. No party shall have any authority to act, or attempt to act, or represent itself, directly or by implication, as an agent of the other or in any manner assume or create or attempt to assume or create, any obligation on behalf of
or in the name of the other, nor shall either be deemed the agent or employee of the other. 

  

	16.	Assignment and Successors. Neither this Agreement nor any obligation of a party hereunder may be assigned by a party without the consent of the other which shall not be
unreasonably withheld, except that each party may assign this Agreement and the rights, obligations and interests of such party, to any of its affiliates without such consent. A change in control of any Party shall be deemed an assignment hereunder.

  
 Confidential - Xenogen Corporation

  

	***	Confidential treatment requested 

	17.	Force Majeure. None of Charles River, Xenogen or XenogenBio shall be liable for failure of or delay in performing obligations set forth in this Agreement, and neither shall
be deemed in breach of its obligations, if such failure or delay is due to natural disasters, explosion, strike, acts of terrorism, war, government requirement, civil or military authority, act of God or any causes beyond the reasonable control of
Charles River, Xenogen or XenogenBio. In event of such force majeure, the party affected thereby shall use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder. 

  

	18.	Dispute Resolution. The parties shall attempt, in good faith, to resolve through negotiations any controversy, claim, or dispute arising out of this Agreement. In the event
that negotiations are not successful, the controversy, claim, or dispute shall be submitted to third party mediation upon terms reasonably acceptable to the parties. If such claim, controversy or dispute is not resolved through mediation, upon
written demand of either party, the claim, controversy or dispute shall be submitted to arbitration before three (3) arbitrators. Such arbitration shall take place in Boston, Massachusetts if Xenogen or XenogenBio is the plaintiff and in New York,
New York if Charles River is the Plaintiff, and shall proceed in accordance with the Commercial Arbitration Rules of the American Arbitration Association and the laws of the Commonwealth of Massachusetts. Within seven (7) calendar days after either
party makes a written demand on the other for arbitration, each of Charles River on the one hand and Xenogen and XenogenBio on the other shall select one (1) arbitrator. A third arbitrator shall be chosen by the arbitrators selected by the parties
involved within thirty (30) days of the demand for arbitration, and shall act as chairman. In the event that any arbitrator is not appointed in the prescribed time period, either party involved may apply to the American Arbitration Association for
the appointment of such arbitrator. A record and transcript of the proceedings shall be maintained. Any award shall be made in writing and in reasonable detail, setting forth the findings of fact and conclusion of law supporting the award. The
determination of a majority of the panel of arbitrators shall be the decision of the arbitrators, which shall be binding regardless of whether one of the parties involved fails or refuses to participate in the arbitration. The decision shall be
enforceable by a court of law, provided that the decision is supported by substantial fact and is without material error of law. All costs of such arbitration, except expert fees and attorneys’ fees, shall be shared equally by the parties
involved in such arbitration. 

  

	19.	Entire Agreement. This Agreement constitutes the entire agreement between Charles River, Xenogen and XenogenBio with respect to the subject matter hereof and supersedes all
prior agreements, promises, understandings and negotiations, whether written or oral, regarding the subject matter hereof. No waiver, consent, modification, amendment or change of the terms of this Agreement shall bind a party unless in writing and
signed by duly authorized representatives of the other parties. 

  

	20.	Severability. In the event that any provision of this Agreement is held by a court of competent jurisdiction to be unenforceable because it is invalid or in conflict with any
law of any relevant jurisdiction, the validity of the remaining provisions shall not be affected, and the rights and obligations of the parties shall be construed and enforced as if the Agreement did not contain the particular provisions held to be
unenforceable and the unenforceable provisions shall be replaced by mutually acceptable provisions which, being valid, legal and enforceable, come closest to the intention of the parties underlying the invalid or unenforceable provision.

  

 Confidential - Xenogen Corporation 

	21	Governing Law. The validity, construction and interpretation of this Agreement, and the rights and duties of the parties, shall be governed by and construed in accordance
with the laws of the Commonwealth of Massachusetts. 

  

	22.	Authority. Each party has full power and authority to enter into and perform this Agreement and the person signing this Agreement on behalf of each party hereto has been
properly authorized and empowered to enter into this Agreement. 

  

	23.	Joint and Several Liability. Xenogen and XenogenBio shall be jointly and severally liable under this Agreement and Charles River may proceed against either one without having
commenced any action or obtained any judgment against the other. 

  
 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year indicated above. 
  

			
	 Charles River Laboratories, Inc.

		
	By:	 	 /s/ Illegible

	 	 	

			
	 Print Name:
	 	 
	 	 	

			
	 Title:
	 	 
	 	 	

  

			
	 Xenogen Biosciences Corporation:

		
	By:	 	 /s/ Pamela Reilly Contag

	 	 	

			
	 Print Name:
	 	 Pamela Reilly Contag

			
	 Title:
	 	 CEO

  

			
	 Xenogen Corporation:

		
	By:	 	 /s/ Pamela Reilly Contag

	 	 	

			
	 Print Name:
	 	 Pamela Reilly Contag

			
	 Title:
	 	 President

  

 Confidential - Xenogen Corporation 

 EXHIBIT A 
 DESCRIPTION OF CREATION SERVICES 
  
 Creation Services is broadly defined as the standard and custom services offered to create transgenic, knockout or mutant animals. May involve part of (e.g., creation of construct only) or the entire creation process, including: 

 
 Transgenic Production Programs (pronuclear
microinjection) including: 
  

	 	•	DNA microinjection 

  

	 	•	Gene integration analysis 

  

	 	•	Design and generation of transgenes 

  

	 	•	Custom microinjection programs 

  
 Custom Gene Targeting Programs 
  

	 	•	Transfection using targeting construct through breeding of mice 

  

	 	•	ES cell transfection 

  

	 	•	Blastocyst injection 

  

	 	•	Custom gene targeting programs 

  
 It is understood that Creation Services specifically excludes sublicenses to distribute the resulting transgenic, knockout or mutant animals or any follow-on or other
services related to those animals. 
  
 It is understood that Creation Services
includes specialty custom creation projects, including projects to create custom light producing transgenic animals (LPTATM animal models). 
  

 Confidential - Xenogen Corporation 

 EXHIBIT B 
 MARKETING PLAN 
  
 *** 
  
 Confidential - Xenogen Corporation

  

	***	Confidential treatment requested 

 Charles River Laboratories 2003 Tradeshow Schedule 
  
 Distribution Date: 1-27-03 
  
 Gray Line Items = Indicates shows/events under consideration, non-exhibit events, cancelled
events 
 White Line Items = Confirmed shows 
  
 Listing is subject to change 
  
 CRL will cover the cost of one Booth/Exhibit Hall registration for a Xenogen attendee, if desired, for any show. Publication, posters, platform presentations by a Xenogen scientist are encouraged. 
 A Xenogen representative is welcome to participate in pre-show planning meetings. Xenogen literature 
 will be 
 Available and distributed as noted. 
  
 Past = Not available due to the date 
 N/R = Not
Recommended for Xenogen 
 Optional = Xenogen may want to attend (pre-show planning meeting may help to make that decision). 
  

									
	 DATE

	  	 TRADESHOW / EVENT

	  	 LOCATION

	  	 BUSINESS

	  	Xenogen Brochures

	 JAN 14
	  	Albert Einstein College of Medicine	  	Bronx, NY	  	Rodent/Transgenic	  	Past
	 JAN 27-31
	  	Sales Meeting	  	Boston, MA	  	N/A	  	Past
	 JAN 30-31
	  	SEAALAS	  	Atlanta, GA	  	Sponsor Only	  	Past
	 JAN 30
	  	Texas Medical Center BioFaire	  	Houston, TX	  	Rodent/Transg	  	Past
	 JAN 31
	  	Texas A & M University BioFaire	  	College Station, TX	  	Rodent/Transg	  	Past
	 FEB 5
	  	Harvard Vendor Day	  	Cambridge, MA	  	Rodent/Transgenic	  	Past
	 	  	 	  	 	  	 	  	Past, N/R
	 	  	 	  	 	  	 	  	Past
	 	  	 	  	 	  	 	  	Past, N/R
	 	  	 	  	Lake Buena Vista, FL	  	 	  	Past
	 	  	 	  	Washington, DC	  	 	  	Past, N/R
	 FEB 25
	  	Pediatric Drug Development Post Conference Workshop	  	Washington, DC	  	DDS	  	Past, N/R
	 FEB 27
	  	University of Florida BioFaire	  	Gainesville, FL	  	Rodent/Transgenic	  	Past
	 MARCH 3-4
	  	 	  	La Jolla, CA	  	 	  	Past, N/R
	 MARCH 5-7
	  	 	  	La Jolla, CA	  	 	  	Past, N/R
	 	  	 	  	Durham, NC	  	Rodent/Transgenic	  	Past
	 	  	Research Triangle Park BioFaire	  	Durham, NC	  	Rodent/Transgenic	  	Past
	 MARCH 9-13
	  	SOT	  	Salt Lake City, UT	  	All Businesses	  	Past
					
	 	  	 •      C. Adams, L. Arp, D. Auyeung,
T. Barfknecht, J. Barnett, G. Beattie, J. Beaver, L. Black, K. Bonnette, K. Braybrook, T. Buono, M. Butt, R. Cavallaro, C. Chan, G. Chellman, T. Claggett, C. Clifford, M. Cunningham, D. Curry, S. Cyrek, G. Dearlove, K. Denny, T.
Dicke, S. Eldridge, R. Erwin, H. Esber, K. Ewing, D Forbes, J. Foster
	  	 •      M. Giknis, N. Gillett, M. Godin, A. Hall,
H, Helle, S. Hersey, A. Hoberman, B. Hobson, M. Horner, I. Jester, J. Kapeghian, T. Kern, D. Kornbrust, G. Knutsen, J. LaBarge, P. Lappin, D. Learn
	  	 •      A. Trombino, L. Turner, M. Willis, A. Wilson, S. Wilson, R. York, T. Zoetis
	  	 
					
	 MAR 12
	  	WA Branch AALAS Spring Trade Fair	  	Seattle, WA	  	Rodent/Transgenic	  	Past

  

 Confidential - Xenogen Corporation 

									
	 •      MAR 19-21
 DATE
 CORRECTION!
	  	District 4 AALAS	  	Raleigh, NC	  	Rodent/Transgenic	  	Past
	 MARCH 20
	  	University of Arizona BioFaire	  	Tucson, AZ	  	Rodent/Transg	  	Past
	 APRIL 2-4
	  	 •      Texas/Louisiana Joint AALAS
	  	Galveston, TX	  	Rodent/Transgenic	  	Yes
	 APRIL 3
	  	Washington University Bio Faire	  	St. Louis, MO	  	Rodent/Transgenic	  	Yes
	 APRIL 5-9
	  	 	  	 	  	Rodent/Transgenic	  	Yes
	 	  	 	  	 	  	Rodent/Transgenic	  	Yes
	 APR 11-15
	  	Experimental Biology	  	San Diego, CA	  	Consomic, ZDF, Surgical, DSI, Transgenic	  	Yes
	 APRIL 17
	  	Los Angeles Vendor Showcase	  	Los Angeles, CA	  	 Rodent/Transgenic
 •      LAL
	  	Yes
	 APRIL 24
	  	University of Illinios BioFaire	  	Chicago, IL	  	 Rodent/Transgenic
 •      LAL
	  	Yes
	 APR 24-25
	  	FDA Science Forum	  	Washington, DC	  	N/A	  	N/R
	 APR 30–MAY 3
	  	Society for Biomaterials	  	 	  	 	  	N/R
	 MAY 1
	  	Emory University BioFaire	  	 	  	Rodent/Transgenic	  	Yes
	 MAY 3-7
	  	Wound Healing Society 13th Annual	  	Seattle, WA	  	DDS/Rodent Diabetic Model	  	Optional
	 MAY 4-7
	  	Waterside Monocional B-T-B w/Transgenic BioProcessing	  	San Francisco, CA	  	BPS	  	N/R
	 MAY 7
	  	Waterside Monoclonal Workshop	  	San Francisco, CA	  	BPS	  	N/R
	 	  	ARVO	  	Fort Lauderdale, FL	  	 	  	N/R
	 MAY 8-9
	  	Transgenics BioProcessing B-T-B w/Waterside (May 4-7)	  	San Francisco, CA	  	BPS	  	N/R
	 MAY 13-17
	  	Am Society of Hypertension	  	NY, NY	  	Rodent CV Models, Surgical Svcs, DSI / DDS	  	Optional
	 MAY 14-15
	  	Quad AALAS	  	Albany, NY	  	Rodent	  	Yes
	 	  	CHI Recombinant Antibodies	  	 	  	 	  	N/R
	 	  	Baylor College of Medicine Vendor	  	 	  	 	  	Yes
	 MAY 15
	  	University of Utah BioFaire	  	Salt Lake City, UT	  	 Rodent/Transg
 •      LAL
	  	N/R
	 MAY 18-22
	  	ASM	  	Washington, DC	  	LAL	  	N/R
	 MAY 28
	  	San Diego Discussion Group	  	San Deigo, CA	  	 	  	N/R
	 JUNE 2003
	  	DDS Symposium	  	TBD	  	 	  	N/R
	 JUNE ??
	  	 	  	 	  	DDS	  	N/R
	 JUNE 2-4
	  	 	  	 	  	 	  	N/R
	 JUNE 4-8
	  	ASGT	  	Washington, DC	  	BPS/DDS/Transg	  	Yes
	 JUNE 8-12
	  	ASMS	  	Montreal, CANADA	  	DDS	  	N/R
	 	  	 	  	 	  	 	  	Yes
	 JUNE 10-13
	  	FDA/IAB “State of the Art Analytical Methods for Characterization of Biological Products	  	Bethesda, MD	  	N/A	  	N/R
	 JUNE 11
	  	University of CA Berkley	  	Berkeley, CA	  	Rodent/Transg	  	Yes
	 JUNE 12
	  	San Franscisco Vendor Showcase	  	San Francisco, CA	  	 Rodent/Transg
 LAL
	  	Yes
	 JUNE 14-16
	  	ADA	  	New Orleans, LA	  	Rodent Disease Models	  	Yes

  

 Confidential - Xenogen Corporation 

									
	 JUNE 14-17
	  	AAMI	  	Long Beach, CA	  	LAL	  	N/R
	 JUNE 15-19
	  	DIA	  	San Antonio, TX	  	Milestone	  	N/R
	 JUNE 16-19
	  	STP	  	Savannah, GA	  	DDS	  	N/R
	 JUNE 16-19
	  	CRL Short Course	  	Danvers, MA	  	 	  	2004 Possible
	 JUNE 18-19
	  	 Beyond Genome 2003
 Proteomics. Applications in
Therapeutic and Diagnostic Development
	  	San Diego, CA	  	PROTEOMICS	  	Optional
	 JUNE 18-21
	  	Endocrine	  	Philadelphia, PA	  	Rodent Disease Models/Transgenic	  	Yes
	 JUNE 18-20
	  	LAMA Annual Meeting	  	San Juan, PR	  	Attendees ONLY	  	N/R
	 JUNE 19
	  	University of PA	  	Philadelphia, PA	  	Rodent/Transgenic	  	Yes
	 JUNE 21-25
	  	SNM 50th Annual Meeting	  	New Orleans, LA	  	LAL	  	N/R
	 JUNE 22-25
	  	BIO	  	Washington, DC	  	All Businesses	  	Yes
	 JUNE 25
	  	University of Wisconsin	  	Madison, WI	  	Rodent Consomic/Transgenic	  	Yes
	 JULY 12-14
	  	Raw Materials & Contract Services	  	Newport Beach, CA	  	BPS	  	N/R
	 JULY 17
	  	University of Michigan BioFaire	  	Ann Arbor, MI	  	Rodent/Transgenic	  	Yes
	 JULY 31
	  	University of Pittsburgh BioFaire	  	Pittsburg, PA	  	Rodent/Transgenic	  	Yes
	 AUG 6
	  	University of Minnesota	  	Minneapolis, MN	  	 Rodent
 LAL
	  	Optional
	 AUG 10-15
	  	IBC’s Drug Discovery Technology	  	Boston, MA	  	DDS	  	Optional
	 AUG 12
	  	University of Texas, San Antonio	  	San Antonio, TX	  	Rodent/Transgenic	  	Yes
	 AUG 14
	  	Texas Medical Center, Houston	  	Houston, TX	  	Rodent/Transgenic	  	Yes
	 AUG 28
	  	University of WA, Seattle	  	Seattle, WA	  	 Rodent/Transgenic
 LAL
	  	Yes
	 FALL 2003
	  	Co-Sponsor NESOT Meeting w/Novartis	  	TBD	  	DDS	  	N/R
	 SEPT ??
	  	Cal Tech	  	Pasadena, CA	  	Rodent/Transgenic	  	Yes
	 SEPT 22-25
	  	Cell & Tissue	  	Memphis, TN	  	BPS	  	N/R
	 SEPT ??
	  	NCAB AALAS	  	??	  	Rodent/Transgenic	  	Yes
	 SEPT 4
	  	University of CA, San Diego	  	San Diego, CA	  	 Rodent/Transgenic
 LAL
	  	Yes
	 SEPT 8-12
	  	PDA/FDA Joint Regulatory Cont.	  	Washington, DC	  	LAL/BPS	  	N/R
	 SEPT 14-17
	  	PBA	  	Orlando, FL	  	DDS	  	N/R
	 SEPT 17-18
	  	Harvard Research Festival	  	Boston, MA	  	 Rodent/Transgenic
 LAL
	  	Yes
	 SEPT 18
	  	Ohio State University BioFaire	  	Columbus, OH	  	Rodent/Transgenic	  	Yes
	 SEPT 21-24
	  	Heart Failure	  	Las Vegas, NV	  	Rodent Disease Models, DDS	  	Optional
	 SEPT 24
	  	University of Missouri BioFaire	  	Columbia, MO	  	Rodent/Transgenic	  	N/R
	 OCT 1-4
	  	Academy of Surgical Research	  	St. Louis, MO	  	Rodent Surg/DDS	  	N/R

  

 Confidential - Xenogen Corporation 

									
	 OCT 6-10
	  	Genomics on Target	  	Boston, MA	  	GTS, TG, Consomic Rats, DDS	  	Yes
	 OCT 11-15
	  	NAASO	  	Ft Lauderdale, FL	  	Rodent Disease Models	  	Optional
	 OCT 15
	  	University of CA, Irvine BioFaire	  	Irvine, CA	  	Rodent/Transge nic	  	Yes
	 OCT 12-16
	  	National AALAS	  	Seattle, WA	  	All Businesses	  	Yes
	 OCT 12-16
	  	ISSX	  	Providence, RI	  	MAP / BAC	  	N/R
	 OCT 16-17
	  	NIH Research Festival	  	Bethesda, MD	  	Rodent/Transge nic	  	Yes
	 OCT 26 –30
	  	AAPS	  	Salt Lake City, UT	  	MAP /BAC/ BPS	  	Optional
	 NOV ??
	  	Viral Vectors	  	Las Vegas, NV	  	BPS	  	N/R
	 NOV ??
	  	Viral Vectors Workshop	  	Las Vegas, NV	  	 	  	N/R
	 NOV ??
	  	Biopharmaceutical Production Wk Recovery & Purification Portion Only	  	West Coast	  	BPS	  	N/R
	 NOV 2-5
	  	ACT	  	Washington, DC	  	DDS	  	N/R
	 NOV 8-13
	  	Neuroscience	  	New Orleans, LA	  	Rodent/Transg/ DDS	  	Yes
	 NOV 9-12
	  	AHA	  	Orlando, FL	  	Rodent / DDS	  	Optional
	 NOV 10-12
	  	PDA	  	Atlanta, GA	  	LAL	  	N/R
	 NOV 12-17
	  	ASN	  	San Diego, CA	  	Rodent	  	Yes
	 NOV 20
	  	University of Alabama BioFaire	  	Birmingham, AL	  	 Rodent/Transge
 nic
	  	Yes
	 DEC 11
	  	LSU & Tulane University Health Sciences Centers	  	New Orleans, LA	  	Rodent/Transge nic	  	Yes

  

 Confidential - Xenogen Corporation 

	•	DISTRICT 8 AALAS WILL NOT BE HELD IN 2003 DUE TO NATIONAL AALAS LOCATION ON WEST COAST (Seattle, WA) 

  
 ~KEY~ 
  
 AACR ~ American Association for Cancer Research 
 AACC ~ Am
Association of Clinical Chemistry 
 AAMI ~ Assoc for the Advancement of Medical Instru. 
 AAPS ~ Am Association of Pharmaceutical Scientists 
 AALAS ~ Am Association for Lab Animal Science 

ACC ~ American College of Cardiology 
 ACS ~ American College of Surgeons 
 ACS ~ American Chemical Society 
 ACT ~ American College of Toxicology 
 ACVP ~ Am College of Vet
Pathologists 
 ADA ~ American Diabetes Association 
 AFSTAL ~ French Assoc for Lab Animal Science 
 AHA ~ American Heart Association 
 ARVO ~ Assoc for Rsch in Vision in Ophthalmology 
 ASCB ~
American Society for Cell Biology 
 ASGT ~ Am Society of Gene Therapy 
 ASHP ~ Am Soc of Health-System Pharmacists 
 ASM ~ American Society of Microbiology 
 ASMS ~ American Society for Mass Spectrometry 
 ASN ~ American
Society of Nephrology 
 ASBMB ~ Am.Society/Biochemistry/Molecular/Bio 
 AUA ~ American Urological Association 
 BGVV ~ (translation) Institution of healthy, consumer protection and
vet medicine 
 BIO ~ Biotechnology Industry Organization 
 CBI ~ Center for Business Intelligence 
 CHI ~ Cambridge Healthtech Institute 
 DIA ~ Drug Information Association 
 DSI ~ Data Sciences
International 
 ENDO ~ The Endocrine Society 
 ETS ~
European Teratology Society 
 HBM ~ Human Brain Mapping 
 IAT ~ Institute of Animal Technology Cong 
 IBC ~ International Business Communications 
 IRA ~ Inflammation Research Association 
 ISSX ~ Intn’l Soc
for the Study of Xenobiogen 
 LASA ~ Laboratory Animal Science Winter 
 MBC ~ Massachusetts Biotech Council 
 MDM ~ Medical Design & Manufacturing 
 NAASO ~ North Am Assoc for the Study of Obesity 
 NEDMDG ~ New
England Drug Metabolism Discussion Group 
 NIH ~ National Institutes of Health 
  
  
  

 Confidential - Xenogen Corporation 

 EXHIBIT C 
 ANNUAL FEE PAYMENT SCHEDULE 
  

					
	 Days after Effective Date or
 Anniversary of Effective Date*

	  	2003

	 	2004

	 90 days
	  	***	 	***
	 120 days
	  	***	 	***
	 270 days
	  	***	 	***
	 360 days
	  	***	 	***
	 December 31**
	  	Prorated amount of next
payment, next payment is less
December 31st payment	 	Prorated amount of next
payment, next payment is less
December 31st, payment

  

	*	Effective day is day one 

  

	**	*** 

  
 Confidential - Xenogen Corporation 
  

	***	Confidential treatment requested 

 EXHIBIT D 
 EXCLUSIONS FROM REVENUE 
  
 For
these third party customers, only revenue for Creation Services in calendar year 2003 that is above the amount stated below will be paid as described above. 
  
 *** 
  
 Confidential - Xenogen Corporation 
  

	***	Confidential treatment requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00066-of-00352.parquet"}]]